Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Transcription factors are involved in a large number of human diseases such as cancers for
which they account for about 20% of all oncogenes identified so far. For long time, with the …

Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major
pharmacological challenge. The clinical success of thalidomide analogues demonstrates …

Genes that drive the proliferation, survival, invasion and metastasis of malignant cells have
been identified for many human cancers,,–. Independent studies have identified cell death …

One of the unusual features of germinal center (GC) B cells is that they manifest many
hallmarks of cancer cells. Accordingly, most B‐cell neoplasms originate from the GC …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that
utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI) …

The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies,
including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with …

The most aggressive B cell lymphomas frequently manifest extranodal distribution and carry
somatic mutations in the poorly characterized gene TBL1XR1. Here, we show that TBL1XR1 …

B-cell lymphoma 6 (BCL6) inhibition is a promising mechanism for treating hematological
cancers but high quality chemical probes are necessary to evaluate its therapeutic potential …

BCL6 was initially discovered as an oncogene in B-cell lymphomas, where it drives the
malignant phenotype by repressing proliferation and DNA damage checkpoints and …